Low-dose inhibitors of HK2 can effectively target HCC cells, and when combined with metformin or sorafenib, they significantly enhance apoptosis and inhibit tumor growth in human HCC cells (14). The gene discussed is HK2; the disease is hepatocellular carcinoma.